99m Tc MIBI prone scintimammography in breast Paget's disease: a case report. 1999

S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
Servizio Speciale di Oncologia, Dipartimento di Medicina Sperimentale e Patologia, I-00161 Rome, Italy.

A 99m Tc MIBI prone scintimammography (PSM) was performed in a case of underlying Paget's disease of the breast. 99m Tc MIBI PSM showed a diffuse scintigraphic image like a spread of uptake from the deeply located zones of the breast toward epidermis. In vivo, 99m Tc MIBI PSM represents the spread of neoplastic Paget's cells probably attracted by chemotactic factors released by keratinocytes. This spread in Paget's disease is correlated to neu oncogene overexpression which increases the metastatic activity as a consequence of motility enhancement and growth stimulation effect. These scintigraphic images suggest that 99m Tc MIBI PSM could be relevant in management of Paget's disease of the breast.

UI MeSH Term Description Entries
D008327 Mammography Radiographic examination of the breast. 3D-Mammography,Digital Breast Tomosynthesis,Digital Mammography,X-ray Breast Tomosynthesis,3D Mammography,3D-Mammographies,Breast Tomosyntheses, Digital,Breast Tomosyntheses, X-ray,Breast Tomosynthesis, Digital,Breast Tomosynthesis, X-ray,Digital Breast Tomosyntheses,Digital Mammographies,Mammographies,Mammographies, Digital,Mammography, Digital,X ray Breast Tomosynthesis,X-ray Breast Tomosyntheses
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009378 Neoplasms, Multiple Primary Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites. Neoplasms, Synchronous,Neoplasms, Synchronous Multiple Primary,Multiple Primary Neoplasms,Multiple Primary Neoplasms, Synchronous,Synchronous Multiple Primary Neoplasms,Synchronous Neoplasms,Multiple Primary Neoplasm,Neoplasm, Multiple Primary,Neoplasm, Synchronous,Primary Neoplasm, Multiple,Primary Neoplasms, Multiple,Synchronous Neoplasm
D010144 Paget's Disease, Mammary An intraductal in situ carcinoma of the breast, characterized clinically by eczema-like inflammatory skin changes and histologically by infiltration of the dermis by malignant cells (Paget's cells). Paget's Disease of Breast,Mammary Paget Disease,Mammary Paget's Disease,Paget Disease of Breast,Paget Disease, Mammary,Paget's Disease of the Breast,Paget's Disease of the Nipple,Paget's Disease of the Nipple and Areola,Pigmented Mammary Paget Disease,Disease, Mammary Paget,Disease, Mammary Paget's,Mammary Pagets Disease,Paget Disease, Breast,Pagets Disease, Breast,Pagets Disease, Mammary
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002278 Carcinoma in Situ A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane. Carcinoma, Intraepithelial,Carcinoma, Preinvasive,Intraepithelial Neoplasms,Neoplasms, Intraepithelial,Intraepithelial Carcinoma,Intraepithelial Neoplasm,Neoplasm, Intraepithelial,Preinvasive Carcinoma
D002630 Chemotactic Factors Chemical substances that attract or repel cells. The concept denotes especially those factors released as a result of tissue injury, microbial invasion, or immunologic activity, that attract LEUKOCYTES; MACROPHAGES; or other cells to the site of infection or insult. Chemoattractant,Chemotactic Factor,Chemotaxin,Chemotaxins,Cytotaxinogens,Cytotaxins,Macrophage Chemotactic Factor,Chemoattractants,Chemotactic Factors, Macrophage,Macrophage Chemotactic Factors,Chemotactic Factor, Macrophage,Factor, Chemotactic,Factor, Macrophage Chemotactic

Related Publications

S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
September 2000, Clinical nuclear medicine,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
December 1999, Cancer biotherapy & radiopharmaceuticals,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
February 2000, Annals of nuclear medicine,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
August 1996, Nuclear medicine and biology,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
December 2006, Clinical nuclear medicine,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
December 2001, Nuclear medicine communications,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
June 2005, Clinical nuclear medicine,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
October 2001, Clinical nuclear medicine,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
April 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
S Mezi, and F Scopinaro, and A Marzullo, and E Sallusti, and V David, and M Ierardi, and N S Tiberio, and M Modesti
January 2009, Hellenic journal of nuclear medicine,
Copied contents to your clipboard!